Collegium Pharmaceutical, Inc (COLL) stock
COLLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 14/3048% below fair value
$25.93+0.38 (+1.49%)
Close on Nov 18, 2026Market cap $844.17MP/E 20.9Yield –
Collegium Pharmaceutical free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Collegium Pharmaceutical's free cash flow for the twelve months ending Jun 30, 2026 was $328.28M, up 62.7% year over year. For fiscal 2025 it was $327.58M, up 61.1% from the year before. The highest annual figure on record is $327.58M in fiscal 2025.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $327.58M | +61.1% |
| FY2024 | Dec 31, 2024 | $203.33M | -25.9% |
| FY2023 | Dec 31, 2023 | $274.29M | +123.7% |
| FY2022 | Dec 31, 2022 | $122.61M | +20.7% |
| FY2021 | Dec 31, 2021 | $101.61M | +15.0% |
| FY2020 | Dec 31, 2020 | $88.40M | +314.1% |
| FY2019 | Dec 31, 2019 | $21.35M | -87.0% |
| FY2018 | Dec 31, 2018 | $163.91M | – |
| FY2017 | Dec 31, 2017 | -$68.01M | – |
| FY2016 | Dec 31, 2016 | -$75.53M | – |
| FY2015 | Dec 31, 2015 | -$21.93M | – |
| FY2014 | Dec 31, 2014 | -$17.96M | – |
| FY2013 | Dec 31, 2013 | -$16.74M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $70.83M | -2.1% |
| Q1 FY2026 | Mar 31, 2026 | $56.84M | +4.1% |
| Q4 FY2025 | Dec 31, 2025 | $122.36M | +45.5% |
| Q3 FY2025 | Sep 30, 2025 | $78.25M | – |
| Q2 FY2025 | Jun 30, 2025 | $72.37M | +7.8% |
| Q1 FY2025 | Mar 31, 2025 | $54.60M | -11.0% |
| Q4 FY2024 | Dec 31, 2024 | $84.07M | +14.9% |
| Q3 FY2024 | Sep 30, 2024 | -$9.24M | -112.5% |
| Q2 FY2024 | Jun 30, 2024 | $67.13M | -32.6% |
| Q1 FY2024 | Mar 31, 2024 | $61.37M | +123.2% |
| Q4 FY2023 | Dec 31, 2023 | $73.17M | +11.9% |
| Q3 FY2023 | Sep 30, 2023 | $73.95M | +73.4% |
| Q2 FY2023 | Jun 30, 2023 | $99.67M | +149.2% |
| Q1 FY2023 | Mar 31, 2023 | $27.50M | – |
| Q4 FY2022 | Dec 31, 2022 | $65.39M | +83.2% |
| Q3 FY2022 | Sep 30, 2022 | $42.66M | +151.2% |
| Q2 FY2022 | Jun 30, 2022 | $39.99M | +38.8% |
| Q1 FY2022 | Mar 31, 2022 | -$25.42M | -226.2% |
| Q4 FY2021 | Dec 31, 2021 | $35.68M | +69.1% |
| Q3 FY2021 | Sep 30, 2021 | $16.98M | -46.6% |
| Q2 FY2021 | Jun 30, 2021 | $28.81M | -33.0% |
| Q1 FY2021 | Mar 31, 2021 | $20.14M | – |
| Q4 FY2020 | Dec 31, 2020 | $21.10M | +42.9% |
| Q3 FY2020 | Sep 30, 2020 | $31.78M | +573.5% |
| Q2 FY2020 | Jun 30, 2020 | $43.03M | +212.9% |
| Q1 FY2020 | Mar 31, 2020 | -$7.51M | – |
| Q4 FY2019 | Dec 31, 2019 | $14.77M | -63.6% |
| Q3 FY2019 | Sep 30, 2019 | $4.72M | -87.9% |
| Q2 FY2019 | Jun 30, 2019 | $13.75M | -75.0% |
| Q1 FY2019 | Mar 31, 2019 | -$11.89M | -140.6% |
| Q4 FY2018 | Dec 31, 2018 | $40.52M | – |
| Q3 FY2018 | Sep 30, 2018 | $39.12M | – |
| Q2 FY2018 | Jun 30, 2018 | $54.97M | – |
| Q1 FY2018 | Mar 31, 2018 | $29.31M | – |
| Q4 FY2017 | Dec 31, 2017 | -$13.47M | – |
| Q3 FY2017 | Sep 30, 2017 | -$12.91M | – |
| Q2 FY2017 | Jun 30, 2017 | -$17.92M | – |
| Q1 FY2017 | Mar 31, 2017 | -$23.72M | – |
| Q4 FY2016 | Dec 31, 2016 | -$23.63M | – |
| Q3 FY2016 | Sep 30, 2016 | -$19.53M | – |
See a number that looks wrong?